Allergan and AbbVie Report the Results for TrenibotulinumtoxinE (BoNT/E) In P-III Trials for the Treatment of Glabellar Lines
Shots:
- The P-III clinical trials (M21-500) & (M21-508) evaluates trenibotulinumtoxinE (BoNT/E) vs PBO in patients (n=947) with moderate to severe glabellar lines (GL) for up to 12wks. across the US, Canada & Europe
- The results from both studies depicted a statistically significant improvement in the Facial Wrinkle Scale with BoNT/E vs PBO at day 7 whereas the onset of efficacy was seen at 8hrs. & efficacy duration for 2-3wks. post drug administration
- The company is currently evaluating BoNT/E under P-III clinical trials with results expected by the YE 2023. BoNT/E is a first-in-class, short-acting neurotoxin and Allergan plans to work with next-gen neurotoxins for Aesthetics portfolio
Ref: PR Newswire | Image: Allergan
Related News:- Allergan Reports Results of Vuity in P-III (VIRGO) Trial for the Treatment of Presbyopia or Age-Related Blurry Near Vision
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
